Attaching importance and practicing integrated management of chronic kidney disease_West China Medical Journal

Authors：

LAN Lan , HAN Fei ,  CHEN Jianghua

Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P. R. China;

Corresponding author：

CHEN Jianghua, Email: chenjianghua@zju.edu.cn

Keywords：

Chronic kidney disease; Delaying the deterioration of renal function; Integrated management

DOI：

10.7507/1002-0179.201907013

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Chronic kidney diease has a high incidence. It is a major disease that seriously endangers human health. The integrated management of chronic kidney disease, through etiological treatment of chronic kidney disease, delaying the deterioration of renal function, and the combination of hemodialysis, peritoneal dialysis and kidney transplantation for end-stage kidney disease treatment, is a scientific and effective full-course management of chronic kidney disease. The integrated management of chronic kidney disease is the key to reduce the mortality and disability rates. At the same time, it is a more important and far-reaching task to emphasize early popularization of science, screening, prevention and intervention to reduce the incidence of kidney disease.

Citation： LAN Lan, HAN Fei, CHEN Jianghua. Attaching importance and practicing integrated management of chronic kidney disease. West China Medical Journal, 2019, 34(7): 719-722. doi: 10.7507/1002-0179.201907013 Copy

1.	Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet, 2013, 382(9888): 260-272.
2.	王善志, 朱永俊, 李国铨, 等. 中国成人慢性肾脏病患病率的Meta分析结果及对比. 中华肾脏病杂志, 2018, 34(8): 579-586.
3.	Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet, 2017, 389(10075): 1238-1252.
4.	梅长林, 邬碧波. 医防结合构建慢性肾脏病三级防治新体系. 第二军医大学学报, 2018(1): 1-5.
5.	Musso G, Cassader M, Cohney S, et al. Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities. Diabetes Care, 2016, 39(10): 1830-1845.
6.	Herrington WG, Preiss D, Haynes R, et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J, 2018, 11(6): 749-761.
7.	Kalantar-Zadeh K, Cano NJ, Budde K, et al. Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol, 2011, 7(7): 369-384.
8.	朱运锋, 谌贻璞, 芮宏亮, 等. 虫草菌粉对慢性马兜铃酸肾病大鼠模型肾间质纤维化的保护作用. 中华医学杂志, 2007, 87(38): 2667-2671.
9.	Banham GD, Flint SM, Torpey N, et al. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet, 2018, 391(10140): 2619-2630.
10.	Uehara M, McGrath MM, Ohori S, et al. Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ. Nat Commun, 2017, 8(1): 951.
11.	Sethi S, Najjar R, Peng A, et al. Allocation of the highest quality kidneys and transplant outcomes under the new kidney allocation system. Am J Kidney Dis, 2019, 73(5): 605-614.
12.	Jiang H, Wu J, Zhang X, et al. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center. Am J Transplant, 2009, 9(8): 1853-1858.
13.	Dugast E, David G, Oger R, et al. Broad impairment of natural killer cells from operationally tolerant kidney transplanted patients. Front Immunol, 2017, 8: 1721.
14.	Alessandrini A, Turka LA. FOXP3-positive regulatory T cells and kidney allograft tolerance. Am J Kidney Dis, 2017, 69(5): 667-674.
15.	陈江华. 提高血液透析患者长期生存率所面临的挑战. 中华肾病杂志, 2006, 22(3): 133-134.
16.	Locatelli F, Karaboyas A, Pisoni RL, et al. Mortality risk in patients on hemodiafiltration versus hemodialysis: a 'real-world' comparison from the DOPPS. Nephrol Dial Transplant, 2018, 33(4): 683-689.
17.	Ronco C, Marchionna N. Expanded haemodialysis: from operational mechanism to clinical results. Nephrol Dial Transplant, 2018, 33(Suppl_3): iii41-iii47.
18.	Tessema LB, Anuja S, Kopple JD. Is it important to prevent and treat protein-energy wasting in chronic kidney disease and chronic dialysis patients?. J Ren Nutr, 2018, 28(6): 369-379.
19.	Post A, Ozyilmaz A, Westerhuis R, et al. Complementary biomarker assessment of components absorbed from diet and creatinine excretion rate reflecting muscle mass in dialysis patients. Nutrients, 2018, 10(12): 1872.
20.	Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int, 2017, 92(1): 26-36.
21.	Sukul N, Zhao J, Fuller DS, et al. Patient-reported advantages and disadvantages of peritoneal dialysis: results from the PDOPPS. BMC Nephrology, 2019, 20(1): 116.
22.	Li PK, Chow KM, Van de Luijtgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol, 2017, 13(2): 90-103.
23.	Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int, 2016, 36(5): 481-508.

1. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet, 2013, 382(9888): 260-272.
2. 王善志, 朱永俊, 李国铨, 等. 中国成人慢性肾脏病患病率的Meta分析结果及对比. 中华肾脏病杂志, 2018, 34(8): 579-586.
3. Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet, 2017, 389(10075): 1238-1252.
4. 梅长林, 邬碧波. 医防结合构建慢性肾脏病三级防治新体系. 第二军医大学学报, 2018(1): 1-5.
5. Musso G, Cassader M, Cohney S, et al. Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities. Diabetes Care, 2016, 39(10): 1830-1845.
6. Herrington WG, Preiss D, Haynes R, et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J, 2018, 11(6): 749-761.
7. Kalantar-Zadeh K, Cano NJ, Budde K, et al. Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol, 2011, 7(7): 369-384.
8. 朱运锋, 谌贻璞, 芮宏亮, 等. 虫草菌粉对慢性马兜铃酸肾病大鼠模型肾间质纤维化的保护作用. 中华医学杂志, 2007, 87(38): 2667-2671.
9. Banham GD, Flint SM, Torpey N, et al. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet, 2018, 391(10140): 2619-2630.
10. Uehara M, McGrath MM, Ohori S, et al. Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ. Nat Commun, 2017, 8(1): 951.
11. Sethi S, Najjar R, Peng A, et al. Allocation of the highest quality kidneys and transplant outcomes under the new kidney allocation system. Am J Kidney Dis, 2019, 73(5): 605-614.
12. Jiang H, Wu J, Zhang X, et al. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center. Am J Transplant, 2009, 9(8): 1853-1858.
13. Dugast E, David G, Oger R, et al. Broad impairment of natural killer cells from operationally tolerant kidney transplanted patients. Front Immunol, 2017, 8: 1721.
14. Alessandrini A, Turka LA. FOXP3-positive regulatory T cells and kidney allograft tolerance. Am J Kidney Dis, 2017, 69(5): 667-674.
15. 陈江华. 提高血液透析患者长期生存率所面临的挑战. 中华肾病杂志, 2006, 22(3): 133-134.
16. Locatelli F, Karaboyas A, Pisoni RL, et al. Mortality risk in patients on hemodiafiltration versus hemodialysis: a 'real-world' comparison from the DOPPS. Nephrol Dial Transplant, 2018, 33(4): 683-689.
17. Ronco C, Marchionna N. Expanded haemodialysis: from operational mechanism to clinical results. Nephrol Dial Transplant, 2018, 33(Suppl_3): iii41-iii47.
18. Tessema LB, Anuja S, Kopple JD. Is it important to prevent and treat protein-energy wasting in chronic kidney disease and chronic dialysis patients?. J Ren Nutr, 2018, 28(6): 369-379.
19. Post A, Ozyilmaz A, Westerhuis R, et al. Complementary biomarker assessment of components absorbed from diet and creatinine excretion rate reflecting muscle mass in dialysis patients. Nutrients, 2018, 10(12): 1872.
20. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int, 2017, 92(1): 26-36.
21. Sukul N, Zhao J, Fuller DS, et al. Patient-reported advantages and disadvantages of peritoneal dialysis: results from the PDOPPS. BMC Nephrology, 2019, 20(1): 116.
22. Li PK, Chow KM, Van de Luijtgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol, 2017, 13(2): 90-103.
23. Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int, 2016, 36(5): 481-508.

Next Article
A brief talk about integrated management strategy of chronic kidney disease in China

West China Medical Journal

Attaching importance and practicing integrated management of chronic kidney disease

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content